Free Trial

€IG Primary Tracker (By Week)

CREDIT SUPPLY


  • Supply picked up this week with EUR 6.75bn in €IG across seven lines from nine issuers with EUR 3.25bn of this coming on Monday alone.
  • Cover for the week was 3x against the YTD total of 3.3x and ranged from 4.7x on Natwest’s EUR 0.75bn 7yr to 2x on Astrazeneza’s EUR 0.75bn 9yr.
  • Fourth tightest average launch spread of the year with five of nine lines launched being single A-rated.
  • NICs were tight across the board with an average of 3.6bp, a 50% trimmed mean of 5.4bp and a median of 5bp; Natwest came in 10bps tight to our FV while Saint-Gobain’s 12yr came in flat as the best performing deals. Atrazeneca’s 9yr, Edenred’s 8yr and Vodafone’s 9yr left the most on the table with NICs of 8bp, 7bp and 7bp respectively.

132 words

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.


  • Supply picked up this week with EUR 6.75bn in €IG across seven lines from nine issuers with EUR 3.25bn of this coming on Monday alone.
  • Cover for the week was 3x against the YTD total of 3.3x and ranged from 4.7x on Natwest’s EUR 0.75bn 7yr to 2x on Astrazeneza’s EUR 0.75bn 9yr.
  • Fourth tightest average launch spread of the year with five of nine lines launched being single A-rated.
  • NICs were tight across the board with an average of 3.6bp, a 50% trimmed mean of 5.4bp and a median of 5bp; Natwest came in 10bps tight to our FV while Saint-Gobain’s 12yr came in flat as the best performing deals. Atrazeneca’s 9yr, Edenred’s 8yr and Vodafone’s 9yr left the most on the table with NICs of 8bp, 7bp and 7bp respectively.